- Home
- Latest news
Latest news
How Johnson & Johnson is working to get medications to people around the world who need them most
In the just-released 2024 Access to Medicine Index, the company ranks among the top 5 improving access to medicines.
6 ways Johnson & Johnson is using AI to help advance healthcare
Artificial intelligence is revolutionizing healthcare—from improving surgical training and procedures to equipping healthcare providers with insights and personalizing care for patients around the world. See how the company is harnessing its extraordinary power.
More from Johnson & Johnson
After their husbands were diagnosed with multiple myeloma, these 3 care partners became health equity activists
Kimberly Alexander, Michelle Ware-Ivy and Marsha Calloway-Campbell learned firsthand that Black individuals develop multiple myeloma at higher rates. That’s why they joined Johnson & Johnson’s That’s My Word® health equity campaign, which builds awareness about the disparities surrounding this rare blood cancer.
What you need to know about Johnson & Johnson’s 2024 third quarter earnings
Check out this infographic breakdown of the company’s third quarter performance, with highlights from its Innovative Medicine and MedTech businesses.
This scientist develops targeted treatments for cancer—here’s what drives and inspires him
Learn more about Zhao, his partnership with Johnson & Johnson and antibody-drug conjugates—a new type of cancer therapy that targets and kills cancer cells without harming healthy cells.
What’s the difference between a heart attack and cardiac arrest?
Both are life-threatening heart-health emergencies, but they are two distinct conditions with different causes and treatment. Here’s what a cardiologist wants you to know.
Meet the medical engineer behind the innovative heart pump that revolutionized cardiac health
Drawing on his fascination with airplane technology, Thorsten Siess, Ph.D., came up with an idea that became the Impella heart pump. Now, 25 years since it entered the market, this groundbreaking device has helped more than 330,000 patients recover from heart injuries.
How Johnson & Johnson is fighting counterfeit medical products
Fake medication and compromised devices are part of a global market that poses a significant threat to the health of patients. Here’s how the company’s Global Brand Protection team helps keep people safe.
Photo courtesy of GBP LATAM team
Press releases
Johnson & Johnson MedTech Announces CE Mark Approval for Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter
The Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter offers electrophysiologists the ability to switch between radiofrequency and pulsed field energy in a single, fully integrated catheter CE Mark supported by the SmartfIRE study on the Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter for the treatment of paroxysmal atrial fibrillation (AFib) Additional milestones announced include complete enrollment of the SmartPulse and PulseSmart trials
Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis
Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad population of antibody positive adult patients: anti-AChR, anti-MuSK, anti-LRP4
Johnson & Johnson’s Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer’s Disease
Building on decades of the Company’s Alzheimer’s research, two differentiated investigational therapies aim to slow pathological tau in distinct populations Fast Track designations reinforce J&J’s commitment to Alzheimer’s disease development and the potential of its precision approach
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) shows statistically significant and clinically meaningful improvement in overall survival versus osimertinib
Median overall survival improvement expected to exceed one year First and only regimen with a survival benefit over current standard of care in first-line treatment of EGFR-mutated lung cancer
